Baird Incrementally Bullish on Axovant Sciences (AXON) Following Alzheimer's Conference
Tweet Send to a Friend
Baird analyst Brian Skorney reiterated an Outperform rating and $29 price target Axovant Sciences (NYSE: AXON), saying they are incrementally ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
